. 2020 Oct 1;9(11):1075–1084. doi: 10.1530/EC-20-0195
This work is licensed under a Table 1.
Baseline characteristics of the participants.
| Metformin (n = 19) | Metformin and OCP (n = 23) | OCP (n = 23) | |
|---|---|---|---|
| Age (years) | 31 (24–33) | 30 (24–31) | 28 (25–32) |
| Weight (kg) | 73.6 (69.2–83.5) | 80.2 (70.5–86.0) | 86.0 (62.1–88.8) |
| BMI (kg/m2) | 26.0 (24.1–29.6) | 27.6 (24.3–31.3) | 28.0 (22.9–31.8) |
| Waist-hip ratio | 0.84 (0.76–0.88) | 0.84 (0.77–0.88) | 0.86 (0.76–0.87) |
| Total testosterone (nmol/L) | 2.0 (1.3–2.9) | 1.6 (1.3– 2.3) | 1.7 (1.4–2.7) |
| Free testosterone (nmol/L) | 0.035 (0.027–0.050) | 0.029 (0.022–0.045) | 0.033 (0.019–0.053) |
| Ferriman Gallway-score | 5 (0–11) | 8 (3–12) | 5 (2–9) |
| SHBG (nmol/L) | 44.0 (32.0–62.0) | 47.0 (32.0–72.0) | 52.0 (36.0–82.0) |
| Glucose (mmol/L) | 5.3 (4.9–5.4) | 5.2 (5.0–5.6) | 5.2 (5.0–5.6) |
| Insulin (pmol/L) | 61 (49–91) | 70 (44–79) | 67 (50–120) |
| C-peptide (pmol/L) | 687 (618–991) | 673 (589–787) | 748 (582–972) |
| HOMA-IR | 14.3 (11.1–19.3) | 15.3 (11.2–19.5) | 16.0 (12.1–28.9) |
| Total cholesterol (mmol/L) | 4.7 (4.4–5.1) | 4.4 (4.0 –4.7) | 4.3 (3.9–5.1) |
| LDL cholesterol (mmol/L) | 2.8 (2.6–3.3) | 2.6 (2.4–2.8) | 2.6 (2.2–3.3) |
| HDL cholesterol (mmol/L) | 1.5 (1.2–1.8) | 1.3 (1.2–1.5) | 1.3 (1.2–1.4) |
| Triglyceride (mmol/L) | 1.0 (0.7–1.3) | 0.9 (0.7–1.3) | 0.9 (0.6–1.4) |
| Fat, arms (kg) | 3.2 (2.5–4.0) | 2.8 (2.3–3.8) | 3.4 (2.5–4.3) |
| Fat, legs (kg) | 10.5 (8.2–12.6) | 9.6 (8.6–11.3) | 11.2 ( 7.0–14.0) |
| Fat, trunk (kg) | 15.9 (13.4–19.5) | 16.4 (11.0–19.6) | 18.9 (12.1–22.0) |
Data are presented as medians (IQR). There were no differences between the groups in any of the variables (one-way ANOVA, Tukey post hoc).
HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low density lipoprotein; SHBG, sex hormone binding globulin.